{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:11:15Z","timestamp":1774584675897,"version":"3.50.1"},"reference-count":15,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T00:00:00Z","timestamp":1691884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Unmet needs remain in later lines chronic myeloid leukemia (CML): the response rate and the overall survival of resistant patients in the chronic phase who changed a second-generation TKI in the second line with another TKI with similar action are usually poor, while the off-target toxicities and the potential development of mutations increase. The recent approval of asciminib, a STAMP inhibitor, in the third line, has the potential to soon change the therapeutic algorithm for this subset of patients. Here, we report the results of a GIMEMA survey assessing the number of patients currently treated in the third line in Italy, the current approach in later lines by Italian physicians, and the future role of this drug according to the reason to switch to asciminib (resistance and\/or intolerance), as well as the perceptions about the future position of this agent.<\/jats:p>","DOI":"10.3390\/jcm12165267","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T10:40:31Z","timestamp":1692009631000},"page":"5267","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Italian Physicians\u2019 Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[{"name":"GIMEMA Foundation, 00182 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa U.O.C. Ematologia, Ospedale S. Eugenio, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6346-4791","authenticated-orcid":false,"given":"Daniela","family":"Cilloni","sequence":"additional","affiliation":[{"name":"Ematologia, Azienda Ospedaliera Mauriziano Umberto I, 10128 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-4766","authenticated-orcid":false,"given":"Monica","family":"Messina","sequence":"additional","affiliation":[{"name":"GIMEMA Foundation, 00182 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Soddu","sequence":"additional","affiliation":[{"name":"GIMEMA Foundation, 00182 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[{"name":"Hematology Unit, IRCCS Azienda Ospedaliero, University of Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-158X","authenticated-orcid":false,"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[{"name":"CTC U.O di Ematologia con Trapianto di Midollo Osseo, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Fazi","sequence":"additional","affiliation":[{"name":"GIMEMA Foundation, 00182 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0812","authenticated-orcid":false,"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[{"name":"Ematologia, Fondazione IRCCS CA\u2019 Granda, Ospedale Maggiore Policlinico, 20122 Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-5187","authenticated-orcid":false,"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Brotzu, Presidio Ospedaliero A. Businco, Struttura Complessa Ematologia E CTMO, 09124 Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Gozzini","sequence":"additional","affiliation":[{"name":"Struttura Ospedaliera Dipartimentale Ematologia, AOU Careggi, 50139 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Intermesoli","sequence":"additional","affiliation":[{"name":"Struttura Complessa Ematologia, Ospedale di Bergamo, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariella","family":"D\u2019Adda","sequence":"additional","affiliation":[{"name":"UO Ematologia, ASST Degli Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2563-4125","authenticated-orcid":false,"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa Ematologia, AOU Federico II, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1002\/cam4.3071","article-title":"How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the Italian medicines agency (AIFA)","volume":"9","author":"Breccia","year":"2020","journal-title":"Cancer Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: Current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023-common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjh.18323","article-title":"Asciminib for chronic myeloid leukaemia: Next questions","volume":"199","author":"Shanmuganathan","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","article-title":"Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results","volume":"37","author":"Mauro","year":"2023","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs. bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: Longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.1182\/blood-2022-169110","article-title":"Dynamics of response and response factors in patients with chronic myeloid leukemia in chronic phase (CML-CP) after >2 prior tyrosine kinase inhibitors (TKIs) in the phase 3 Ascembl study","volume":"140","author":"Hughes","year":"2022","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"ref_11","first-page":"90","article-title":"A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase","volume":"11","author":"Breccia","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","article-title":"Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: Primary results of the phase 4 BYOND study","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/01.HS9.0000969648.55133.e1","article-title":"Real-World Efficacy Profile of Asciminib in An Italian, Multi-Resistant Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patient Population","volume":"7","author":"Breccia","year":"2023","journal-title":"HemaSphere"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Breccia, M., Chiodi, F., Nardozza, A.P., Valsecchi, D., Perrone, V., Sangiorgi, D., Giacomini, E., Rendace, M.C., Coco, P., and Premoli, E. (2022). Real-world analysis of therapeutic management and disease burden in chronic myeloid leukemia patients with later lines in Italy. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133597"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/16\/5267\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:32:36Z","timestamp":1760128356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/16\/5267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,13]]},"references-count":15,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["jcm12165267"],"URL":"https:\/\/doi.org\/10.3390\/jcm12165267","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,13]]}}}